CJ Bioscience, Inc. (KOSDAQ:311690)

CJ Bioscience Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	13,289	8,309	64,095	49,324	62,060	13,255
Short-Term Investments	48,000	67,000	-	-	18,020	-
Trading Asset Securities	-	-	-	-	-	26,020
Cash & Short-Term Investments	61,289	75,309	64,095	49,324	80,080	39,275
Cash Growth	23.18%	17.50%	29.95%	-38.41%	103.89%	26.35%
Accounts Receivable	220.01	72.57	160.91	303.82	233.62	99.46
Other Receivables	316.76	623.2	178.66	523.06	474.16	257.47
Receivables	536.77	695.77	339.57	826.88	707.78	356.93
Inventory	162.93	128.75	157.82	76.16	145.83	364.31
Prepaid Expenses	322.02	294.56	355.71	446.57	259.18	499.9
Other Current Assets	246.18	333.6	262.22	258.72	362.03	592.63
Total Current Assets	62,556	76,762	65,210	50,932	81,555	41,089
Property, Plant & Equipment	6,471	8,907	12,707	14,364	9,856	19,991
Long-Term Investments	2	2	2	2	0	-
Other Intangible Assets	11,774	12,499	12,397	1,016	114.13	103.95
Other Long-Term Assets	1,601	1,439	811.16	25,075	24,830	12,178
Total Assets	82,405	99,610	91,128	91,389	116,355	73,362
Accounts Payable	211.43	220.83	122.82	336.65	287.75	708.93
Accrued Expenses	2,408	3,234	3,966	3,996	140.94	169.76
Short-Term Debt	6,185	6,365	3,971	23,588	18,441	-
Current Portion of Leases	1,444	1,824	1,869	1,547	1,361	205.9
Other Current Liabilities	3,733	6,882	4,793	5,511	3,606	1,919
Total Current Liabilities	13,983	18,525	14,722	34,979	23,836	3,004
Long-Term Debt	-	-	-	-	-	35,081
Long-Term Leases	657.51	1,162	2,692	3,831	4,088	479.37
Other Long-Term Liabilities	2,498	2,166	2,152	2,924	577.4	314.4
Total Liabilities	17,210	21,853	19,633	41,734	28,502	38,878
Common Stock	6,533	6,533	4,556	2,939	2,937	1,946
Additional Paid-In Capital	189,419	189,419	151,426	108,066	112,186	40,993
Retained Earnings	-132,101	-119,067	-85,951	-62,738	-28,035	-8,763
Comprehensive Income & Other	1,344	872.04	1,465	1,389	765.25	307.61
Shareholders' Equity	65,195	77,757	71,496	49,655	87,853	34,484
Total Liabilities & Equity	82,405	99,610	91,128	91,389	116,355	73,362
Total Debt	8,287	9,351	8,533	28,966	23,891	35,766
Net Cash (Debt)	53,002	65,958	55,562	20,357	56,190	3,509
Net Cash Growth	29.75%	18.71%	172.93%	-63.77%	1501.15%	-88.44%
Net Cash Per Share	4710.85	7111.76	7843.75	3463.50	13214.21	908.96
Filing Date Shares Outstanding	13.07	13.07	9.11	5.88	5.87	3.89
Total Common Shares Outstanding	13.07	13.07	9.11	5.88	5.87	3.89
Working Capital	48,574	58,236	50,488	15,953	57,718	38,085
Book Value Per Share	4989.85	5951.30	7845.89	8446.71	14957.10	8859.45
Tangible Book Value	53,421	65,257	59,098	48,640	87,739	34,380
Tangible Book Value Per Share	4088.72	4994.63	6485.40	8273.89	14937.67	8832.74
Land	-	-	-	-	-	13,973
Buildings	-	-	-	-	-	2,563
Machinery	-	14,051	13,686	10,339	4,411	3,488
Construction In Progress	-	-	-	521.7	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.